Best time to walk after ProGlide femoral artery closure
Official title: Optimizing Time to Ambulation After ProGlide Closure of Femoral Access: A Randomized Controlled Trial
Run by Chinese Academy of Medical Sciences, Fuwai Hospital · NCT07179536 · Data updated 2026-11-12
This trial will test different times for getting up and walking after ProGlide closure in adults having transfemoral peripheral angiography or endovascular procedures to find a timing that's safe and lets patients ambulate sooner.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | March 30, 2026 |
| Study ends | March 30, 2026 |
| Registry record updated | January 23, 2026 |
| Trial ID | NCT07179536 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults scheduled for transfemoral peripheral angiography or endovascular intervention with a common femoral artery puncture, 6–8F sheath, successful hemostasis with a 6F ProGlide, ABI >0.9, and normal lower-limb mobility are ideal candidates.
✕Probably not a fit
Patients with femoral artery diameter <5 mm, prior vascular complications at the puncture site, abnormal cardiopulmonary function, intraoperative platelet count <80×10⁹/L or thrombolytic use, cognitive impairment, or limited lower-limb mobility are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Patients undergoing transfemoral peripheral angiography or endovascular intervention who achieve hemostasis with a 6F ProGlide device will be enrolled and assigned to predefined ambulation times after the procedure. The study will monitor vascular complications, hematoma, bleeding, limb ischemia, time to ambulation, and patient comfort. Key eligibility includes common femoral artery puncture, use of 6–8F sheaths, and preoperative ABI >0.9, while those with small femoral vessels, prior puncture-site complications, significant cardiopulmonary disease, or coagulopathy are excluded. The aim is to identify an ambulation schedule that balances patient safety with shorter bed rest and greater efficiency.
Why it matters
Potential benefit: If successful, the findings could allow patients to get up sooner after ProGlide closure, reducing bed rest, discomfort, and length of stay without increasing vascular complications.
How similar studies have gone: Smaller reports, including work by Sekhar et al., have shown early ambulation is feasible after ProGlide closure in coronary procedures, but evidence specific to transfemoral peripheral interventions is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Scheduled for peripheral angiography or endovascular intervention via transfemoral access. * Femoral artery puncture site located at the common femoral artery. * Use of 6-8F vascular sheath. * Hemostasis achieved with 6F ProGlide closure device (defined as no active bleeding, no hematoma formation, and no ischemia of the punctured limb after closure). * Preoperative ankle-brachial index (ABI) \> 0.9 on both sides. * Conscious, cooperative, and with normal lower limb mobility. Exclusion Criteria: * Undergoing carotid artery intervention. * Femoral artery diameter \< 5 mm, or effective lumen \< 5 mm due to plaque burden. * History of vascular complications at the puncture site. * Abnormal cardiopulmonary function. * Intraoperative platelet count \< 80 × 10⁹/L, or use of thrombolytic agents. * Cognitive impairment, uncooperative, or limited lower limb mobility.
Where it's running
-
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Hui Dong, MD — Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
- Study coordinator: Hui Dong, MD
- Email: donghui666@sina.com
- Phone: 86-010-88322385
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Single-needle distal return for long-term AV fistula care
This trial tests a single-needle method that draws blood from your arm fistula and returns it through a foot or lower-leg vein to see if it reduces damage and the need for repeat procedures in adults on thrice-weekly hemodialysis.
-
New device to improve intravenous therapy safety
This study is testing a new device that aims to make intravenous treatments safer and more effective for patients by reducing risks like infections and catheter problems.
-
Comparing three types of arteriovenous fistulas for dialysis access
This study is trying to find out which of three types of arteriovenous fistulas works best for people on dialysis to help them get the best access for their treatment.
-
SelfWrap-Assisted Arteriovenous Fistulas for Chronic Kidney Disease
This study is testing if a new wrap called SelfWrap can make it safer and more effective for people with chronic kidney disease to have a new arteriovenous fistula created.
-
Device for easier access to dialysis through arteriovenous fistulas
This study is testing a new device called VenaSure to see if it can make it easier and safer for people on hemodialysis to access their arteriovenous fistulas.
-
Comparing radial and femoral access methods for cardiac catheterization
This study is testing whether using the wrist or the groin for heart catheterization is better for patients in terms of satisfaction and complications.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.